However, the application of PLA2G7 inhibition in cancer therapy is still in its early stages, and there are concerns about the ability of inhibitors to effectively target and modulate cancer-associated PLA2G7 activity in vivo [19,43,44]. This evidence concerns the gene PLA2G7 and cancer.